Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency

NCT00161707 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Alpha1-antitrypsin Deficiency

Interventions

DRUG: Aerosolized, Recombinant Alpha 1-Antitrypsin

Sponsor

Baxalta now part of Shire

Collaborators

[object Object]